Immunotherapy in genitourinary cancers: achievements and perspectives

World J Urol. 2021 May;39(5):1317. doi: 10.1007/s00345-021-03726-1.

Authors

Evanguelos Xylinas¹, Mathieu Roumiguié², Paul Sargos³

Affiliations

¹ Department of Urology, Bichat-Claude Bernard Hospital, Assistance-Publique-Hôpitaux de Paris, Université de Paris, Paris, France. evanguelosxylinas@hotmail.com.
² Department of Urology, CHU Rangueil IUCT Oncopole Toulouse, Toulouse, France.
³ Department of Radiotherapy, Institut Bergonié, Bordeaux, France.

PMID: 34003335
DOI: 10.1007/s00345-021-03726-1

No abstract available

Publication types

Editorial

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use*
B7-H1 Antigen
CTLA-4 Antigen
Humans
Immunotherapy / adverse effects
Immunotherapy / methods*
Programmed Cell Death 1 Receptor
Urogenital Neoplasms / immunology*
Urogenital Neoplasms / pathology
Urogenital Neoplasms / therapy*

Substances

Antineoplastic Agents, Immunological
B7-H1 Antigen
CTLA-4 Antigen
CTLA4 protein, human
PDCD1 protein, human
Programmed Cell Death 1 Receptor